A multi-institutional retrospective study of carbon-ion radiotherapy for non-squamous cell malignant tumors of the nasopharynx

Subanalysis of Japan Carbon-Ion Radiation Oncology Study Group study 1402 HN

Japan Carbon-Ion Radiation Oncology Study Group

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: This multi-institutional retrospective study focused on the clinical outcome of carbon-ion radiotherapy (C-ion RT) for non-squamous cell malignant tumors of the nasopharynx. Methods: The Japan Carbon-ion Radiation Oncology Study Group collected and analyzed data for 43 patients with non-squamous cell malignant tumors of the nasopharynx treated with C-ion RT at four institutions in Japan. Results: Twenty-nine patients had adenoid cystic carcinomas, seven had malignant melanomas, three had adenocarcinomas, two had mucoepidermoid carcinomas, and two had other pathologies. Twenty-six of the 43 patients (61%) had T4 tumors. The most common dose-fractionation schedule was 64 Gy (relative biological effectiveness) in 16 fractions. The median follow-up period was 30 months. The 2-year local control (LC) and overall survival (OS) rates were 88% and 84%, respectively. For late toxicity, one patient developed grade 4 optic nerve disorder and two developed grade 5 pharyngeal hemorrhage. Actual incidence of grade 3 or higher late adverse events was 19%, and included cranial nerve dysfunction, jaw bone necrosis, central nervous system necrosis, and ear inflammation. Conclusions: C-ion RT provided good LC and OS rates with acceptable toxicity for treatment of non-squamous cell malignant tumors of the nasopharynx.

Original languageEnglish
Pages (from-to)6077-6083
Number of pages7
JournalCancer Medicine
Volume7
Issue number12
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Heavy Ion Radiotherapy
Radiation Oncology
Nasopharynx
Japan
Carbon
Retrospective Studies
Ions
Neoplasms
Survival Rate
Relative Biological Effectiveness
Dose Fractionation
Mucoepidermoid Carcinoma
Otitis
Adenoid Cystic Carcinoma
Osteonecrosis
Cranial Nerves
Optic Nerve
Jaw
Melanoma
Appointments and Schedules

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

A multi-institutional retrospective study of carbon-ion radiotherapy for non-squamous cell malignant tumors of the nasopharynx : Subanalysis of Japan Carbon-Ion Radiation Oncology Study Group study 1402 HN. / Japan Carbon-Ion Radiation Oncology Study Group.

In: Cancer Medicine, Vol. 7, No. 12, 01.12.2018, p. 6077-6083.

Research output: Contribution to journalArticle

@article{c65e53dc4d2346a6a75aad832331d2c0,
title = "A multi-institutional retrospective study of carbon-ion radiotherapy for non-squamous cell malignant tumors of the nasopharynx: Subanalysis of Japan Carbon-Ion Radiation Oncology Study Group study 1402 HN",
abstract = "Background: This multi-institutional retrospective study focused on the clinical outcome of carbon-ion radiotherapy (C-ion RT) for non-squamous cell malignant tumors of the nasopharynx. Methods: The Japan Carbon-ion Radiation Oncology Study Group collected and analyzed data for 43 patients with non-squamous cell malignant tumors of the nasopharynx treated with C-ion RT at four institutions in Japan. Results: Twenty-nine patients had adenoid cystic carcinomas, seven had malignant melanomas, three had adenocarcinomas, two had mucoepidermoid carcinomas, and two had other pathologies. Twenty-six of the 43 patients (61{\%}) had T4 tumors. The most common dose-fractionation schedule was 64 Gy (relative biological effectiveness) in 16 fractions. The median follow-up period was 30 months. The 2-year local control (LC) and overall survival (OS) rates were 88{\%} and 84{\%}, respectively. For late toxicity, one patient developed grade 4 optic nerve disorder and two developed grade 5 pharyngeal hemorrhage. Actual incidence of grade 3 or higher late adverse events was 19{\%}, and included cranial nerve dysfunction, jaw bone necrosis, central nervous system necrosis, and ear inflammation. Conclusions: C-ion RT provided good LC and OS rates with acceptable toxicity for treatment of non-squamous cell malignant tumors of the nasopharynx.",
author = "{Japan Carbon-Ion Radiation Oncology Study Group} and Takanori Abe and Tatsuya Ohno and Masashi Koto and Yusuke Demizu and Hiroaki Suefuji and Hiroshi Tsuji and Tomoaki Okimoto and Yoshiyuki Shioyama and Yoshiyuki Shioyama and Katsuyuki Shirai and Kenji Nemoto and Takashi Nakano and Tadashi Kamada and Hiroyuki Katoh",
year = "2018",
month = "12",
day = "1",
doi = "10.1002/cam4.1884",
language = "English",
volume = "7",
pages = "6077--6083",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - A multi-institutional retrospective study of carbon-ion radiotherapy for non-squamous cell malignant tumors of the nasopharynx

T2 - Subanalysis of Japan Carbon-Ion Radiation Oncology Study Group study 1402 HN

AU - Japan Carbon-Ion Radiation Oncology Study Group

AU - Abe, Takanori

AU - Ohno, Tatsuya

AU - Koto, Masashi

AU - Demizu, Yusuke

AU - Suefuji, Hiroaki

AU - Tsuji, Hiroshi

AU - Okimoto, Tomoaki

AU - Shioyama, Yoshiyuki

AU - Shioyama, Yoshiyuki

AU - Shirai, Katsuyuki

AU - Nemoto, Kenji

AU - Nakano, Takashi

AU - Kamada, Tadashi

AU - Katoh, Hiroyuki

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: This multi-institutional retrospective study focused on the clinical outcome of carbon-ion radiotherapy (C-ion RT) for non-squamous cell malignant tumors of the nasopharynx. Methods: The Japan Carbon-ion Radiation Oncology Study Group collected and analyzed data for 43 patients with non-squamous cell malignant tumors of the nasopharynx treated with C-ion RT at four institutions in Japan. Results: Twenty-nine patients had adenoid cystic carcinomas, seven had malignant melanomas, three had adenocarcinomas, two had mucoepidermoid carcinomas, and two had other pathologies. Twenty-six of the 43 patients (61%) had T4 tumors. The most common dose-fractionation schedule was 64 Gy (relative biological effectiveness) in 16 fractions. The median follow-up period was 30 months. The 2-year local control (LC) and overall survival (OS) rates were 88% and 84%, respectively. For late toxicity, one patient developed grade 4 optic nerve disorder and two developed grade 5 pharyngeal hemorrhage. Actual incidence of grade 3 or higher late adverse events was 19%, and included cranial nerve dysfunction, jaw bone necrosis, central nervous system necrosis, and ear inflammation. Conclusions: C-ion RT provided good LC and OS rates with acceptable toxicity for treatment of non-squamous cell malignant tumors of the nasopharynx.

AB - Background: This multi-institutional retrospective study focused on the clinical outcome of carbon-ion radiotherapy (C-ion RT) for non-squamous cell malignant tumors of the nasopharynx. Methods: The Japan Carbon-ion Radiation Oncology Study Group collected and analyzed data for 43 patients with non-squamous cell malignant tumors of the nasopharynx treated with C-ion RT at four institutions in Japan. Results: Twenty-nine patients had adenoid cystic carcinomas, seven had malignant melanomas, three had adenocarcinomas, two had mucoepidermoid carcinomas, and two had other pathologies. Twenty-six of the 43 patients (61%) had T4 tumors. The most common dose-fractionation schedule was 64 Gy (relative biological effectiveness) in 16 fractions. The median follow-up period was 30 months. The 2-year local control (LC) and overall survival (OS) rates were 88% and 84%, respectively. For late toxicity, one patient developed grade 4 optic nerve disorder and two developed grade 5 pharyngeal hemorrhage. Actual incidence of grade 3 or higher late adverse events was 19%, and included cranial nerve dysfunction, jaw bone necrosis, central nervous system necrosis, and ear inflammation. Conclusions: C-ion RT provided good LC and OS rates with acceptable toxicity for treatment of non-squamous cell malignant tumors of the nasopharynx.

UR - http://www.scopus.com/inward/record.url?scp=85056772507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056772507&partnerID=8YFLogxK

U2 - 10.1002/cam4.1884

DO - 10.1002/cam4.1884

M3 - Article

VL - 7

SP - 6077

EP - 6083

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 12

ER -